Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Nanomedicine. 2016 Mar 29;12(7):1827–1831. doi: 10.1016/j.nano.2016.03.004

Figure 2.

Figure 2

(A) Schematic representation of the AntihypoxamiR Functionalized Gramicidin Lipid Nanoparticles (AFGLN). (B) The zeta potential of the AFGLN at different pH. Shaded region represents the pH range in chronic wounds. (C) Representative nanoparticle tracking analysis (NanoSight) showing particles size and concentration of the empty GLN (devoid of any cargo), AFGLN packed with scrambled oligos (AFGLNscramble) and AFGLN packed with anti-miR-210 (AFGLNmiR-210) (n=4).